Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82,051,282
-
Total 13F shares
-
5,090,631
-
Share change
-
+4,861,631
-
Total reported value
-
$84,547,000
-
Price per share
-
$16.71
-
Number of holders
-
29
-
Value change
-
+$80,720,029
-
Number of buys
-
27
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q1 2021
As of 31 Mar 2021,
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,090,631 shares.
The largest 10 holders included
Ally Bridge Group (NY) LLC, WELLINGTON MANAGEMENT GROUP LLP, Logos Global Management LP, BVF INC/IL, Cormorant Asset Management, LP, Point72 Asset Management, L.P., RA CAPITAL MANAGEMENT, L.P., Ghost Tree Capital, LLC, Atlas Venture Advisors, Inc., and D. E. Shaw & Co., Inc..
This page lists
28
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.